SRTSMay 7, 2026 at 8:05 PM UTCHealth Care Equipment & Services

Sensus Q1 Revenue Plunges 59% YoY as Largest Customer Orders Collapse, CPT Tailwind Fails to Offset

Read source article

What happened

Sensus Healthcare reported Q1 2026 revenue of $3.4 million, a 59% drop from $8.3 million a year earlier, with the company explicitly noting the decline was driven by the absence of sales to its historically largest customer. The new SRT-specific CPT codes, effective January 1, 2026, were expected to drive a recovery, but Q1 results show no meaningful offset from other channels, including Fair Deal and international. Gross margin likely remained under pressure given the low revenue base and mix shift away from high-margin capital sales, though the press release did not provide full margin details. The balance sheet remains debt-free with $24.5 million cash, providing a buffer, but the cash burn rate may accelerate if revenue does not recover. This result significantly disappoints relative to the master report's base-case expectation of stabilization and gradual improvement, pushing the probability weight toward the bear scenario.

Implication

The Q1 2026 results confirm that Sensus remains highly dependent on a single customer, and the new CPT codes have not driven immediate system purchases. With revenue falling to just $3.4M, the company is burning cash and may need to raise capital if the trend continues. The fair value under the bear case of $3.00 per share now seems more likely, offering limited upside from current levels. Investors should require at least two consecutive quarters of sequential revenue growth and gross margin improvement before considering a position. The thesis that reimbursement improvements would quickly boost demand has been refuted in the near term.

Thesis delta

The Q1 2026 earnings release fundamentally undermines the base-case thesis that new CPT codes would stabilize and gradually improve revenue beginning in early 2026. Instead, revenue crashed 59% YoY to $3.4M, far below even bear-case projections, with no visible diversification benefits from Fair Deal or international channels. The probability of the bear scenario (previously 35%) should be raised significantly, and the 'Wait' rating may need downgrading to 'Avoid' unless there is a clear path to recovery visible in the next quarter.

Confidence

Low